Marinus Pharmaceuticals, Inc. (MRNS) experienced a significant stock decline following the release of disappointing data from its Phase 3 TrustTSC trial for oral ganaxolone in treating seizures associated with tuberous sclerosis complex (TSC). The trial failed to meet its primary endpoint, leading the company to discontinue further ganaxolone development and explore strategic alternatives.